Vaccines against SARS-CoV-2 are urgently required, but early development of vaccines against SARS-CoV-1 resulted in enhanced disease after vaccination. Careful assessment of this phenomena is warranted for vaccine development against SARS CoV-2. Here we report detailed immune profiling after ChAdOx1 nCoV-19 (AZD1222) and subsequent high dose challenge in two animal models of SARS-CoV-2 mediated disease. We demonstrate in rhesus macaques the lung pathology caused by SARS-CoV-2 mediated pneumonia is reduced by prior vaccination with ChAdOx1 nCoV-19 which induced neutralising antibody responses after a single intramuscular administration. In a second animal model, ferrets, ChAdOx1 nCoV-19 reduced both virus shedding and lung pathology. Antibody titre were boosted by a second dose. Data from these challenge models on the absence of enhanced disease and the detailed immune profiling, support the continued clinical evaluation of ChAdOx1 nCoV-19. Lambe, Spencer, Thomas, Gilbert and colleagues report on the detailed immune profile of rhesus macaques and ferrets vaccinated against SARS-CoV-2 under high dose challenge. Their findings indicate that the ChAdOx1 nCoV-19 (AZD1222) the vaccine induces immune responses and reduces disease symptoms in both models, including SARS-CoV-2 mediated pneumonia and virus shedding.
【저자키워드】 viral infection, Live attenuated vaccines, 【초록키워드】 SARS CoV-2, SARS-CoV-2, Vaccine, Vaccine development, High dose, immune response, vaccination, Pneumonia, Immune profile, animal model, virus, SARS-CoV-1, AZD1222, clinical evaluation, ferret, immune profiling, disease, ChAdOx1 nCoV-19, intramuscular, Lung pathology, rhesus macaque, administration, Support, second dose, neutralising antibody response, titre, ferrets, Thomas, caused, subsequent, required, reduced, absence, induce, reduce, the vaccine, disease symptom, 【제목키워드】 SARS-CoV-2, ChAdOx1 nCoV-19, rhesus,